Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Marimed (MRMD) Loans and Notes Receivables (2016 - 2025)

Marimed (MRMD) has disclosed Loans and Notes Receivables for 11 consecutive years, with $866000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Loans and Notes Receivables rose 1565.38% to $866000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $866000.0, a 1565.38% increase, with the full-year FY2024 number at $52000.0, changed 0.0% from a year prior.
  • Loans and Notes Receivables was $866000.0 for Q3 2025 at Marimed, up from $39000.0 in the prior quarter.
  • In the past five years, Loans and Notes Receivables ranged from a high of $2.6 million in Q2 2023 to a low of $39000.0 in Q2 2025.
  • A 5-year average of $557133.2 and a median of $127000.0 in 2021 define the central range for Loans and Notes Receivables.
  • Peak YoY movement for Loans and Notes Receivables: surged 1976.38% in 2022, then plummeted 98.03% in 2024.
  • Marimed's Loans and Notes Receivables stood at $127000.0 in 2021, then soared by 1976.38% to $2.6 million in 2022, then plummeted by 98.03% to $52000.0 in 2023, then changed by 0.0% to $52000.0 in 2024, then surged by 1565.38% to $866000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Loans and Notes Receivables are $866000.0 (Q3 2025), $39000.0 (Q2 2025), and $52000.0 (Q1 2025).